Taysha Gene Therapies, Inc.
TSHA Healthcare Biotechnology
Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024. In the quarter to June 2026, revenue grew 206.8%, EPS fell 44.4%, free cash flow fell 100.3% and total debt rose 20.0%, each against the same quarter a year earlier.
Follow TSHA
Taysha Gene Therapies, Inc. (TSHA) EV/Sales
As of 16 October 2026, Taysha Gene Therapies, Inc. (TSHA) trades at a EV/Sales of 78.8×. Over the past ten years it has ranged from 0.0× (September 2023) to 227× (December 2025); the current reading is higher than 80% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 126× | 211.83% |
| FY2024 | 40.5× | 560.31% |
| FY2023 | 6.1× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 126× | 145.51% |
| Jun 2025 | 51.4× | 23.86% |
| Mar 2025 | 41.5× | 2.54% |
| Dec 2024 | 40.5× | (5.19%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LBRX LB Pharmaceuticals Inc compare | n/m |
| GHRS GH Research PLC compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | 4.8× |
| NKTR Nektar Therapeutics compare | 18.3× |
| TSHA Taysha Gene Therapies, Inc. | 78.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)